Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Short term Debt (2016 - 2023)

Ligand Pharmaceuticals' Short term Debt history spans 9 years, with the latest figure at $76.8 million for Q1 2023.

  • For Q1 2023, Short term Debt changed N/A year-over-year to $76.8 million; the TTM value through Mar 2023 reached $76.8 million, changed N/A, while the annual FY2022 figure was $76.7 million, N/A changed from the prior year.
  • Short term Debt for Q1 2023 was $76.8 million at Ligand Pharmaceuticals, roughly flat from $76.7 million in the prior quarter.
  • Across five years, Short term Debt topped out at $115.0 million in Q2 2022 and bottomed at $14.3 million in Q2 2019.
  • The 3-year median for Short term Debt is $76.6 million (2022), against an average of $63.0 million.
  • The largest YoY upside for Short term Debt was 91.77% in 2019 against a maximum downside of 93.2% in 2019.
  • A 3-year view of Short term Debt shows it stood at $14.3 million in 2019, then surged by 435.84% to $76.7 million in 2022, then grew by 0.12% to $76.8 million in 2023.
  • Per Business Quant, the three most recent readings for LGND's Short term Debt are $76.8 million (Q1 2023), $76.7 million (Q4 2022), and $76.6 million (Q3 2022).